TrialESMO open2026

Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.

K Shitara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.